Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s MRK Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, ...

The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...

In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA ...

Merck has obtained the Food and Drug Administration’s permission for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

“Building on the legacy of KEYTRUDA, we are committed to driving innovation in cancer care with new routes of administration and indications in difficult-to-treat and earlier stages of cancer,” said ...